Post Profile






Outrage of the Month: FDA Senior Leader Ignores Science, Approves Ineffective Drug for a Rare Disease

Read more in Public Citizen's October Health Letter On Sept. 19, 2016, the Food and Drug Administration (FDA) approved eteplirsen (brand name Exondys 51) -- the first drug approved for treating Duchenne muscular dystrophy (DMD) -- despite a disturbing lack of evidence that the drug is actually effective. The approval decision ultimately was made by Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research (CDER) -- the center that reviews and approves drugs -- over the strong objections of scientific experts at the agency who had reviewed the new drug application for eteplirsen.
read more

share

Related Posts


Biotech stock explodes 80% after the FDA approves a key drug (SRPT)

Business & Finance : Business Insider: Money Game

Sarepta Therapeutics shares spiked by as much as 86% in trading on Monday after the US Food and Drug Administration said it approved a key drug. The FDA approved Exondys 51 (eteplirsen), the first drug approved to treat patients wit...

FDA Approves First Drug To Treat Rare Form Of Muscular Dystrophy

Health : The Checkup

The Food and Drug Administration Monday approved the first drug to treat Duchenne muscular dystrophy, a rare and lethal muscle weakening disorder that affects about 15,000 Americans. The FDA’s approva...

Here Are Three Ways To Prevent Tragic Battles Between The FDA And Patients

Business & Finance : Forbes: Business

Last night, a panel of advisors to the Food and Drug Administration voted 7 to 3, with 3 abstentions, that the agency should not approve eteplirsen, a drug for a Duchenne muscular dystrophy, a rare, deadly, muscle-destroying disease...

Approving A Muscular Dystrophy Drug Ignites A Civil War At The FDA

Business & Finance : Forbes: Business

Yesterday, the Food and Drug Administration made history, approving a drug to treat Duchenne muscular dystrophy that works by targeting the genetic mutation at the root of the disease. The decision was unique for reasons that were n...

Sarepta Wins FDA Nod For Embattled DMD Drug -- But With A Catch

Business & Finance : Forbes: Business

Just five days after its main nemesis at the FDA departed the agency, Sarepta Therapeutics has won a long-sought-after approval for eteplirsen, its drug to treat Duchenne muscular dystrophy (DMD). But the company's battle isn't over...

Comments


Copyright © 2016 Regator, LLC